Dementia Japan 27: 277-288, 2013
Peripheral biomarker for mild cognitive impairment and Alzheimer's disease
Kazuhiko Uchida1), Kohji Meno2), Hideaki Suzuki2), Hiroyasu Akazu3), Katsuyoshi Mizukami4), Takashi Asada5)
1)Department of Molecular Oncology, Faculty of Medicine, University of Tsukuba
2)Research Division, MCBI, Inc.
3)Choju Medical Institute, Fukushimura Hospital
4)Sports and Health Promotion, Graduate School of Comprehensive Human Sciences, University of Tsukuba
5)Department of Psychiatry, Faculty of Medicine, University of Tsukuba
Alzheimer's disease (AD) is most common form of dementia. Mild cognitive impairment (MCI) due to AD is symptomatic pre-dementia phase. We have investigated proteins which are involved in sequestration from amyloid (Aβ) peptide, and also low molecular weight protein (peptide) biomarkers for MCI and AD. In peptidomics analysis, we developed technology and know-how to unmask molecular biomarker from high abundant plasma proteins and to quantify the amount of biomarker peptide with high reproducibility. In this review, we survey potential peripheral biomarkers for AD, and introduce our recent activity in omics-based biomarker discovery using highly evaluated clinical samples and data in both segmental and longitudinal study.
Address correspondence to Dr. Kazuhioko Uchida, Department of Molecular Oncology, Faculty of Medicine, University of Tsukuba(1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575, Japan)